Thermo Fisher (TMO) Scientific announced it has received approval from the U.S. Food and Drug Administration for its Oncomine Dx Target Test as a companion diagnostic. The test is approved to identify patients with non-small cell lung cancer whose tumors have HER2 activating mutations, making them eligible for treatment with Boehringer Ingelheim’s HERNEXEOS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Trinity Biotech announces launch of FDA-cleared preeclampsia testing service
- Thermo Fisher’s Strong Market Position and Growth Drive Buy Rating
- Thermo Fisher’s Strong Performance and Strategic Initiatives Justify Buy Rating Amid Industry Recovery
- Positive Outlook and Strategic Growth Plans Bolster Thermo Fisher’s Stock Rating
- Thermo Fisher price target raised to $490 from $450 at Barclays